BIOCQ (Biocept) GF Score: 16/100 (As of Jul. 09, 2026) — 64% Below Median


BIOCQ Biocept Inc BIOCQ
16 GF Score
Price $0.00
View Full Analysis

What is Biocept GF Score?

Biocept BIOCQ 16 GF Score is 16 as of Jul. 09, 2026, which is 64% below its 10-year median of 45.00. GuruFocus rates BIOCQ with a GF Score™ of 16/100.

Biocept has the GF Score of 16, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Biocept might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Biocept  (OTCPK:BIOCQ) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Biocept GF Score Related Terms

BIOCQ vs IDTA, DIGP, ABMC: GF Score Comparison

For the Diagnostics & Research subindustry, Biocept's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocept GF Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's GF Score distribution charts can be found below:

* The bar in red indicates where Biocept's GF Score falls into.


BIOCQ
16GF Score
Biocept Inc BIOCQ
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 16 mean?
Biocept (BIOCQ) has a GF Score of 16 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Biocept and its competitors. This is 64% below median its historical median of 45.00. Over the past decade, Biocept's GF Score has ranged from 9.00 to 69.00.
Is Biocept's GF Score too high?
Biocept's current GF Score of 16 is 64% below median its 10-year median of 45.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 69.00. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's GF Score compare to IDTA and DIGP?
Biocept's GF Score of 16 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Biocept's own GF Score has ranged from 9.00 to 69.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Biocept and its competitors. Biocept's current GF Score is 16, which is 64% below median its own 10-year median of 45.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (BIOCQ) has a current GF Score of 16. The current GF Score is 16, which is 64% below median its 10-year median of 45.00. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Biocept (BIOCQ), the current GF Score is 16 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocept Business Description

Address 9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score

Get the complete analysis for BIOCQ

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price